CytoDyn Names Robert E. Hoffman CEO as Jacob Lalezari Moves to Research Role
CytoDyn appointed Hoffman CEO effective October 20, 2026. Lalezari resigned as CEO on the same date and will become Head of Research and Translational Sciences.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.